Uterine carcinosarcoma

What changed: Uterine carcinosarcoma

Cancer page →

Every dated change on the records linked to Uterine carcinosarcoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Trial result3Milestone5This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordUterine carcinosarcoma
Facts on this page last checked
When this page itself was last checked or edited.

2023 · 3

2022 · 1

2022MilestoneCarboplatin
GOG-0261: carboplatin-paclitaxel non-inferior to ifosfamide-paclitaxel
A milestone in how this cancer is treated.

2018 · 1

2018Trial resultPORTEC-3
PORTEC-3 reported
5-year OS 81.

2017 · 1

2017MilestoneTP53
TCGA sequencing confirms a shared clonal origin of both components with frequent TP53 mutation
A milestone in how this cancer is treated.

2014 · 1

2014MilestoneUterine carcinosarcoma
WHO classifies carcinosarcoma as a metaplastic carcinoma rather than a sarcoma
A milestone in how this cancer is treated.

2007 · 1

2007MilestoneIfosfamide
GOG-0161: ifosfamide-paclitaxel improves survival over ifosfamide alone
A milestone in how this cancer is treated.